Clinical Trial Update: CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating abatacept (CTLA4-Ig) for prevention of abnormal glucose tolerance and Type 1 diabetes in relatives at risk has completed, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Abnormal Glucose Tolerance, Type 1 Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2024-06-06